



## **Researcher position in lipid-related metabolic and cardiovascular diseases.**

### **Description of the company**

**Lifesearch** is a biotechnology company created in 2011 and developing R&D projects in collaboration with leading research organizations (INSERM, CNRS, CEA). In this project, the researcher recruited by Lifesearch will work in collaboration with the Institute of Cardiovascular and Metabolic Diseases (I2MC, INSERM UMR1048-Université Paul Sabatier, Toulouse, France), and the team of Dr. Laurent Martinez.

### **Context**

Atherosclerosis and associated cardiovascular diseases still remain the largest cause of mortality worldwide. Furthermore, in parallel with the increasing epidemic of obesity and diabetes, liver diseases, like the non-alcoholic fatty liver disease (NAFLD), have progressively become a serious health concern.

HDL is the primary mediator of the Reverse Cholesterol Transport, a pathway by which excess cholesterol is removed from atherosclerotic plaque and is transported to the liver for subsequent biliary and fecal excretion either as free cholesterol or after transformation into bile acids (BA). In this context, improving HDL-mediated biliary lipid excretion is expected to decrease vascular and hepatic lipid deposition. This opens up new therapeutic perspectives for the development of therapies against atherosclerosis and hepatic steatosis.

Lifesearch has developed a new class of molecules improving HDL functional state with their beneficial properties for cardiovascular and metabolic health. The objective is to achieve a preclinical proof of concept, which will look forward to clinical trials.

### **Task and responsibilities**

The applicant will work in a project team whose activity is dedicated to the study of this new class of molecules and composed of 4 other experienced researchers. He will be expected to set up and conduct pre-clinical research aiming to evaluate the efficacy of this new therapeutic class of molecules. This will include to evaluate their acute and chronic efficacy on preclinical models. He will investigate the vascular and/or metabolic mechanisms underlying therapeutic efficacy. He/she will rely on pharmacological studies performed within the team to conduct lead optimisation phase. Theranostic biomarkers will be also evaluated on different cohorts.

### **Entry requirement**

The candidate should have a PhD. He/she must have an experience and knowledge in experimental models of cardiovascular diseases or lipid disorders, including dyslipidemia and hepatic steatosis. The applicant should ideally have experience in vascular biology, including inflammatory and immune responses and endothelial dysfunction, or in lipid metabolism (particularly BA). He/she should have a good knowledge of statistical and bioinformatic tools. Additional experience with microbial study and pharmacology should be considered a plus. The applicant must be organized, thorough, proactive and a talented problem solver.

### **Position**

The candidate can start as soon as January 1<sup>st</sup>, 2018. Salary is highly attractive and will depend on the candidate's experience.

### **Application procedure**

*Interested applicants should submit a motivation letter, a curriculum vitae including a full list of publications and at least two references to [nsioufi@lifesearch.fr](mailto:nsioufi@lifesearch.fr) and [laurent.martinez@inserm.fr](mailto:laurent.martinez@inserm.fr). Submissions should include the mailing label "Position CVD".*